PROCEPT BIOROBOTICS CORP (PRCT) Stock Price, Quote, News and Overview
NASDAQ:PRCT - Nasdaq - US74276L1052 - Common Stock - Currency: USD
PRCT Quote, Performance and Key Statistics
62.91
-2.14 (-3.29%)
The current stock price of PRCT is 62.91 USD. In the past month the price increased by 14.78%. In the past year, price decreased by -6.9%.
PRCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.95 | 232.41B | ||
| ISRG | INTUITIVE SURGICAL INC | 72.92 | 199.67B | ||
| BSX | BOSTON SCIENTIFIC CORP | 37.81 | 151.04B | ||
| SYK | STRYKER CORP | 30.64 | 146.71B | ||
| MDT | MEDTRONIC PLC | 15.9 | 112.15B | ||
| BDX | BECTON DICKINSON AND CO | 12.31 | 49.71B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.82 | 45.47B | ||
| IDXX | IDEXX LABORATORIES INC | 46.04 | 42.54B | ||
| RMD | RESMED INC | 27.78 | 36.98B | ||
| DXCM | DEXCOM INC | 52.53 | 33.98B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.57 | 32.79B | ||
| STE | STERIS PLC | 26.09 | 23.95B |
Related stock screener links
About PRCT
Company Profile
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 756 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
Company Info
PROCEPT BIOROBOTICS CORP
150 Baytech Drive
San Jose CALIFORNIA US
CEO: Reza Zadno
Employees: 626
Phone: 16502329832
PROCEPT BIOROBOTICS CORP / PRCT FAQ
What is the stock price of PROCEPT BIOROBOTICS CORP today?
The current stock price of PRCT is 62.91 USD. The price decreased by -3.29% in the last trading session.
What is the ticker symbol for PROCEPT BIOROBOTICS CORP stock?
The exchange symbol of PROCEPT BIOROBOTICS CORP is PRCT and it is listed on the Nasdaq exchange.
On which exchange is PRCT stock listed?
PRCT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PROCEPT BIOROBOTICS CORP stock?
17 analysts have analysed PRCT and the average price target is 79.9 USD. This implies a price increase of 27.01% is expected in the next year compared to the current price of 62.91. Check the PROCEPT BIOROBOTICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROCEPT BIOROBOTICS CORP worth?
PROCEPT BIOROBOTICS CORP (PRCT) has a market capitalization of 3.48B USD. This makes PRCT a Mid Cap stock.
How many employees does PROCEPT BIOROBOTICS CORP have?
PROCEPT BIOROBOTICS CORP (PRCT) currently has 626 employees.
What are the support and resistance levels for PROCEPT BIOROBOTICS CORP (PRCT) stock?
PROCEPT BIOROBOTICS CORP (PRCT) has a support level at 56.03 and a resistance level at 65.05. Check the full technical report for a detailed analysis of PRCT support and resistance levels.
Is PROCEPT BIOROBOTICS CORP (PRCT) expected to grow?
The Revenue of PROCEPT BIOROBOTICS CORP (PRCT) is expected to grow by 45.44% in the next year. Check the estimates tab for more information on the PRCT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PROCEPT BIOROBOTICS CORP (PRCT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRCT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRCT, evaluating the profitability, health, valuation and growth aspects
- PROCEPT BIOROBOTICS CORP (PRCT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROCEPT BIOROBOTICS CORP (PRCT) Sales and EPS estimates to see what analysts future expectations are.
- PROCEPT BIOROBOTICS CORP (PRCT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROCEPT BIOROBOTICS CORP (PRCT) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROCEPT BIOROBOTICS CORP (PRCT) Stock Chart to make your own analysis
- PROCEPT BIOROBOTICS CORP (PRCT) Latest news and press-releases to stay up to date.
Does PROCEPT BIOROBOTICS CORP (PRCT) stock pay dividends?
PRCT does not pay a dividend.
When does PROCEPT BIOROBOTICS CORP (PRCT) report earnings?
PROCEPT BIOROBOTICS CORP (PRCT) will report earnings on 2025-07-30, after the market close.
What is the Price/Earnings (PE) ratio of PROCEPT BIOROBOTICS CORP (PRCT)?
PROCEPT BIOROBOTICS CORP (PRCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.7).
What is the Short Interest ratio of PROCEPT BIOROBOTICS CORP (PRCT) stock?
The outstanding short interest for PROCEPT BIOROBOTICS CORP (PRCT) is 11.13% of its float. Check the ownership tab for more information on the PRCT short interest.
PRCT Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to PRCT. When comparing the yearly performance of all stocks, PRCT turns out to be only a medium performer in the overall market: it outperformed 41.38% of all stocks.
PRCT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PRCT. The financial health of PRCT is average, but there are quite some concerns on its profitability.
PRCT Financial Highlights
Over the last trailing twelve months PRCT reported a non-GAAP Earnings per Share(EPS) of -1.7. The EPS increased by 19.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.37% | ||
| ROE | -23.18% | ||
| Debt/Equity | 0.13 |
PRCT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to PRCT. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of 12.34% and a revenue growth 45.44% for PRCT